Reus Sergio, Portilla Joaquín, Gimeno Adelina, Sánchez-Payá José, García-Henarejos J A, Martínez-Madrid Onofre, Usó Jordi, Roca Bernardino, Galindo María José, López-Aldeguer José
Servicio de Enfermedades Infecciosas. Hospital General Universitario de Alicante. Spain.
Enferm Infecc Microbiol Clin. 2004 Mar;22(3):142-9. doi: 10.1016/s0213-005x(04)73054-2.
To assess the factors associated with progression of infection and death in HIV-positive patients with severe immunodepression in the era of highly active antiretroviral therapy (HAART).
We studied 146 HIV-infected patients with < 100 x 10(6)/L CD4+ lymphocytes and positive cytomegalovirus (CMV) serology enrolled between December 1997 and October 1998 and prospectively followed a median of 12.1 months. The main outcome measures were progression of HIV infection, defined as the appearance of a new AIDS-defining disease (CDC category C) or death. HIV viral load, lymphocyte count (CD4+ and CD8+), HAART administration and other clinical variables were evaluated at baseline. CMV viremia (determined by PCR) and HAART efficacy were recorded during follow-up.
Progression was observed in 40% of patients and 17% died. Factors associated with progression or death were CD4+ lymphocyte count less than 50 x 10(6)/L, CD8+ lymphocyte count less than 500 x 10(6)/L, HIV viral load more than 300,000 copies RNA/mL, CMV viremia, and absence or inefficacy of HAART. In the multivariate model, absence of HAART and low CD4+ and CD8+ counts remained statistically associated with progression, but the only variable associated with death was CMV viremia.
In patients with advanced HIV infection, CD4+ and CD8+ cell count and HAART were the most important factors related to progression, and CMV viremia was the strongest predictor of death.
评估在高效抗逆转录病毒治疗(HAART)时代,HIV阳性且免疫严重抑制患者感染进展及死亡的相关因素。
我们研究了1997年12月至1998年10月期间纳入的146例CD4+淋巴细胞计数<100×10⁶/L且巨细胞病毒(CMV)血清学阳性的HIV感染患者,前瞻性随访中位时间为12.1个月。主要结局指标为HIV感染进展,定义为出现一种新的艾滋病定义疾病(疾病控制与预防中心C类)或死亡。在基线时评估HIV病毒载量、淋巴细胞计数(CD4+和CD8+)、HAART治疗情况及其他临床变量。随访期间记录CMV病毒血症(通过PCR测定)及HAART疗效。
40%的患者出现进展,17%的患者死亡。与进展或死亡相关的因素包括CD4+淋巴细胞计数低于50×10⁶/L、CD8+淋巴细胞计数低于500×¹⁰⁶/L、HIV病毒载量超过300,000拷贝RNA/mL、CMV病毒血症以及HAART治疗的缺失或无效。在多变量模型中,HAART治疗的缺失以及低CD4+和CD8+计数与进展仍存在统计学关联,但与死亡相关的唯一变量是CMV病毒血症。
在晚期HIV感染患者中,CD4+和CD8+细胞计数及HAART治疗是与进展相关的最重要因素,而CMV病毒血症是死亡的最强预测因素。